RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors

The mutation of K‐RAS represents one of the most frequent genetic alterations in cancer. Targeting of downstream effectors of RAS, including of MEK and ERK, has limited clinical success in cancer patients with K‐RAS mutations. The reduced sensitivity of K‐RAS‐mutated cells to certain MEK inhibitors...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Oncol
Autors principals: Yuan, Xi, Tang, Zhiyu, Du, Rong, Yao, Zhan, Cheung, Shing‐Hu, Zhang, Xinwen, Wei, Jing, Zhao, Yuan, Du, Yunguang, Liu, Ye, Hu, Xiaoxia, Gong, Wenfeng, Liu, Yong, Gao, Yajuan, Huang, Zhiyue, Cao, Zongfu, Wei, Min, Zhou, Changyou, Wang, Lai, Rosen, Neal, Smith, Paul D., Luo, Lusong
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7400788/
https://ncbi.nlm.nih.gov/pubmed/32336014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12698
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars